Montgomery County Hospital District EMS Service, Conroe, TexasUSA.
Baylor College of Medicine, Department of Emergency Medicine, Houston, TexasUSA.
Prehosp Disaster Med. 2020 Oct;35(5):495-500. doi: 10.1017/S1049023X20000886. Epub 2020 Jul 23.
The utility and efficacy of bolus dose vasopressors in hemodynamically unstable patients is well-established in the fields of general anesthesia and obstetrics. However, in the prehospital setting, minimal evidence for bolus dose vasopressor use exists and is primarily limited to critical care transport use. Hypotensive episodes, whether traumatic, peri-intubation-related, or septic, increase patient mortality. The purpose of this study is to assess the efficacy and adverse events associated with prehospital bolus dose epinephrine use in non-cardiac arrest, hypotensive patients treated by a single, high-volume, ground-based Emergency Medical Services (EMS) agency.
This is a retrospective, observational study of all non-cardiac arrest EMS patients treated for hypotension using bolus dose epinephrine from September 12, 2018 through September 12, 2019. Inclusion criteria for treatment with bolus dose epinephrine required a systolic blood pressure (SBP) measurement <90mmHg. A dose of 20mcg every two minutes, as needed, was allowed per protocol. The primary data source was the EMS electronic medical record.
Forty-two patients were treated under the protocol with a median (IQR) initial SBP immediately prior to treatment of 78mmHg (65-86) and a median (IQR) initial mean arterial pressure (MAP) of 58mmHg (50-66). The post-bolus SBP and MAP increased to 93mmHg (75-111) and 69mmHg (59-83), respectively. The two most common patient presentations requiring protocol use were altered mental status (55%) and respiratory failure (31%). Over one-half of the patients treated required both advanced airway management (62%) and multiple bolus doses of vasopressor support (55%). A single episode of transient severe hypertension (SBP>180mmHg) occurred, but there were no episodes of unstable tachyarrhythmia or cardiac arrest while en route or upon arrival to the receiving hospitals.
These preliminary data suggest that the administration of bolus dose epinephrine may be effective at rapidly augmenting hypotension in the prehospital setting with a minimal incidence of adverse events. Paramedic use of bolus dose epinephrine successfully increased SBP and MAP without clinically significant side effects. Prospective studies with larger sample sizes are needed to further investigate the effects of prehospital bolus dose epinephrine on patient morbidity and mortality.
在全身麻醉和产科领域,血管加压剂推注剂量在血流动力学不稳定患者中的效用和疗效已得到充分证实。然而,在院前环境中,使用推注剂量血管加压剂的证据很少,主要限于重症监护转运使用。低血压发作,无论是创伤性、插管相关还是脓毒性,都会增加患者的死亡率。本研究的目的是评估在单一、大容量的地面紧急医疗服务(EMS)机构治疗的非心搏骤停、低血压患者中,院前推注剂量肾上腺素的疗效和不良事件。
这是一项回顾性、观察性研究,纳入 2018 年 9 月 12 日至 2019 年 9 月 12 日期间因低血压接受推注剂量肾上腺素治疗的所有非心搏骤停 EMS 患者。根据方案接受推注剂量肾上腺素治疗的纳入标准需要收缩压(SBP)测量值<90mmHg。允许根据需要每两分钟给予 20mcg 的剂量。主要数据来源是 EMS 电子病历。
根据方案,42 名患者接受了治疗,初始 SBP 的中位数(IQR)为治疗前即刻 78mmHg(65-86),初始平均动脉压(MAP)的中位数(IQR)为 58mmHg(50-66)。推注后 SBP 和 MAP 分别增加至 93mmHg(75-111)和 69mmHg(59-83)。最常见的两种需要使用方案的患者表现为意识改变(55%)和呼吸衰竭(31%)。接受治疗的患者中超过一半需要进行高级气道管理(62%)和多次推注血管加压剂支持(55%)。仅发生 1 例短暂性重度高血压(SBP>180mmHg),但在转运过程中或到达接收医院时均未发生不稳定心动过速或心搏骤停。
这些初步数据表明,在院前环境中,推注剂量肾上腺素可有效迅速增加低血压,不良事件发生率较低。急救医疗技术员使用推注剂量肾上腺素成功地增加了 SBP 和 MAP,没有明显的副作用。需要更大样本量的前瞻性研究进一步调查院前推注剂量肾上腺素对患者发病率和死亡率的影响。